Breadcrumb Home Multimedia Sue Jacques: managing demand on secondary care - the finance perspective This content relates to the following topics: Access to care NHS finances Share this content Share on Twitter Share on Facebook Share on LinkedIn Share on Email Print this page Article information Posted:Wednesday 08 February 2012 Sue Jacques, President of the Healthcare Financial Management Association, discusses managing demand on secondary care from a finance manager's perspective.This item was recorded at our 2012 conference: Managing demand on secondary care.Related contentVideoCandace Imison: what's the evidence for managing demand on secondary care? Candace Imison looks at opportunities to manage demand on secondary care and the barriers to success. VideoLinda Patterson: reducing demand on secondary care Linda Patterson gives a first hand account of attempts to introduce initiatives and policies to reduce demand on secondary acute care.VideoErik Sande: demand management - how health care technology helps Erik Sande looks at the role technological innovation can play in managing demand for secondary care. Comments Add your comment Your name Email (your email will not be made public) Your job/role Organisation Comment Post comment You may also be interested in Online event Understanding how patients access medicines in England Long read Brexit: the implications for health and social care Brexit has major implications for health and social care in England. Here we look at some of the latest developments that could impact the health and care system in England. Blog NHS medicines provision: a tricky balancing act With medicines spending growing at a time of NHS funding restraint, difficult choices lie ahead for policy-makers. Leo Ewbank assesses the current situation and looks at what the future may hold. Report The rising cost of medicines to the NHS: what’s the story? In the face of rising costs, the NHS is grappling with how to provide access to medicines in an affordable way. Our new briefing explores the NHS’s approach to managing its spending on medicines and choices that policy-makers are likely to face in future.